3,7-dimethyl-1-propargylxanthine has been researched along with Huntington Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfinito, PD; Manzino, L; Rijhsinghani, S; Sonsalla, PK; Wang, SP; Zeevalk, GD | 1 |
| Pèzzola, A; Popoli, P; Reggio, R | 1 |
2 other study(ies) available for 3,7-dimethyl-1-propargylxanthine and Huntington Disease
| Article | Year |
|---|---|
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Drug Administration Routes; Drug Synergism; Electron Transport Complex II; gamma-Aminobutyric Acid; Huntington Disease; Male; Malonates; Mice; Mitochondria; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Theobromine; Tyrosine 3-Monooxygenase; Xanthines | 2003 |
The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electroencephalography; Frontal Lobe; Huntington Disease; Male; Microinjections; Neuroprotective Agents; Purinergic P1 Receptor Antagonists; Quinolinic Acid; Rats; Rats, Wistar; Theobromine | 1999 |